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M elanoma is one of the most deadly malignancies of the eye and ocular surface. The incidence of uveal melanoma (5.6 per million) has remained unchanged for decades, 1 but the incidence of conjunctival melanoma, although rare (0.45-0.8 per million), 2 shows a trend of increasing frequency of diagnosis in Europe and the United States. 3, 4 Telomerase reverse transcriptase (TERT) promoter mutations occur frequently in cutaneous melanoma 5, 6 and in conjunctival melanoma 7 but rarely in cutaneous acral melanoma 8 and uveal melanoma. 7, 9 The frequency of TERT promoter mutations in primary acquired melanosis (PAM) and conjunctival nevi has not yet been described. Here, we investigated the presence of TERT promoter mutations in uveal melanoma, conjunctival melanoma, PAM with atypia, PAM without atypia, and conjunctival nevi in order to elucidate the role of these mutations in tumor progression.
MATERIALS AND METHODS

Patients and Samples
Tissue specimens were obtained from patients with a conjunctival melanocytic lesion or uveal melanoma who had undergone biopsy, excision, or enucleation between 1972 and 2013 at the Erasmus University Medical Center or The Rotterdam Eye Hospital, The Netherlands. Fresh tissue samples were obtained from enucleation specimens of 102 primary uveal melanomas. Conjunctival tissue of all patients diagnosed with conjunctival melanoma or PAM (n ¼ 205), as well as 56 patients with conjunctival nevi, was selected from the electronic archives of the Department of Pathology. Paraffin-embedded tissues were retrieved from the archive, and the amount of tissue present in the blocks was assessed. Samples of 125 patients contained enough material for further study. Next the original glass slides were retrieved from the archive, and the initial diagnoses were reassessed by a pathologist specialized in ophthalmic pathology (RMV), as well as mitosis count, Breslow's thickness, presence of leukocyte infiltration, and necrosis (although rare in melanoma). After confirming diagnosis and assessment, 56 conjunctival nevi samples, 14 PAM without atypia samples, 26 PAM with atypia samples, and 39 conjunctival melanoma samples were used for DNA isolation. Clinical details were obtained from patient records. The study was performed in accordance with the tenets of the Declaration of Helsinki.
DNA Isolation
DNA from uveal melanomas was extracted directly from fresh tumor tissue or frozen tumor using the QIAmp DNA-mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The DNA isolation procedure for the conjunctival nevi, PAM, and conjunctival melanoma samples was performed on formalin-fixed, paraffin-embedded (FFPE) specimens. Criterion for DNA collection was the presence of more than 70% tumor cells. For PAM samples this percentage was not feasible, and a minimum of 20% tumor cells was used for these cases. Microdissection was performed by scraping the tumor cells manually from hematoxylin-stained sections on a glass slide. DNA was extracted from the tissue fragments by incubation overnight at 568C in lysis buffer (A7933; Promega, Leiden, The Netherlands) containing 2 mg/mL proteinase K and 5% Chelex 100 resin. Proteinase K was inactivated at 1008C for 10 minutes, and the DNA was separated from cell debris by centrifugation at maximum speed in a microcentrifuge for 5 minutes.
Chromosomal and Gene Analyses in Uveal Melanoma
Copy number variations in uveal melanoma on chromosomes 1, 3, 6, and 8 were investigated by fluorescence in situ hybridization (FISH) and single nucleotide polymorphism analysis, as described previously. 10 The GNAQ and GNA11 mutation status was determined with Sanger sequencing, 11 and BAP1 expression was examined as reported previously. 12 
Mutation Analysis
SNaPshot analysis to determine the presence of mutations in three mutational hot spots, C228, C242, and C250 ( c h r 5 : 1 , 2 9 5 , 2 2 8 C >T ; c h r 5 : 1 , 2 9 5 , 2 4 2 -2 4 3 C C >T T ; chr5:1,295,250 C>T, respectively; hg19), in the promoter region of TERT was performed essentially as described previously. 13 A 155-bp DNA segment was amplified with upstream primer 5 0 -AGCGCTGCCTGAAACTCG-3 0 and downstream primer 5 0 -CCCTTCACCTTCCAGCTC-3 0 as described above. Subsequently, a single nucleotide probe extension assay was performed with probes designed to anneal to the sites of interest (228 probe: 5 0 -T23 GGCTGGGAGGGCCCGGA-3 0 ; 242-243 probe: 5 0 -T27GGAGGGGGCTGGGCGG-3 0 ; 250 probe: 5 0 -T39 CTGGGCCGGGGACCCGG-3 0 ). These probes were adapted with poly T tails of different lengths to allow separation of the extended products by size. SNaPshot analysis was performed with the SNaPshot multiplex kit (Life Technologies, City, State, Country) according to manufacturer's instructions. Thermal cycler conditions were as follows: 35 cycles of 10 s at 968C and 40 s at 58.58C. SNaPshot products were analyzed on an ABI Prism 3730xl genetic analyzer (Applied Biosystems, Foster City, CA, USA).
Statistical Analyses
All statistical analyses were performed with the Statistical Package for Social Science (IBM SPSS Statistics 20, Chicago, IL, 
RESULTS
Study Cohort
SNaPshot analyses were obtained from the tumor samples of 102 uveal melanomas, 39 conjunctival melanomas, 26 PAM with atypia, 14 PAM without atypia, and 56 conjunctival nevi patients. The samples were primary or recurrent tumors, and seven cases were tested from both primary tumor and recurrences, with identical results. In two PAM cases no reliable results could be obtained because of insufficient quality of the DNA isolated from FFPE tissue. The uveal melanoma group consisted of 55 men and 47 women with a mean age at diagnosis of 61.5 years (range, 21-86 years). Ninety-one tumors were localized in the choroid and 11 in the ciliary body. The mean largest tumor diameter and prominence was 13.4 and 8.2 mm, respectively. Thirty-two of 76 (32.4%) investigated uveal melanomas showed an absent BAP1 expression, and 93 of 99 (91.2%) tumors harbored a mutation in either GNAQ or GNA11. The clinical, histopathologic, and molecular characteristics of the uveal melanomas are shown in Table 1 . The clinical and histopathologic characteristics of the conjunctival melanocytic lesions are listed in Table 2 . The mean age at diagnosis was 41.3, 48.0, 64.0, and 62.5 years for conjunctival nevi, PAM without atypia, PAM with atypia, and conjunctival melanoma, respectively. Recurrences of the melanocytic lesions occurred predominantly in the PAM with atypia and conjunctival melanoma group (57.7% and 48.7%, respectively). No metastases were observed in patients with conjunctival nevi or PAM without atypia. Conjunctival nevi were located at different sites on the conjunctiva, while PAM without atypia was located in the bulbar conjunctiva in 71% of cases and more specifically at the limbus in another 21%. Of the PAM lesions with atypia, 17 were located at the limbus (65%), 3 on the palpebral conjunctiva, 1 on the fornix, 1 on the bulbar conjunctiva, and 1 on the caruncula lacrimalis, and 3 were multifocal. Eighteen (46%) conjunctival melanomas were located at the limbus, 7 on the bulbar conjunctiva, 9 on the palpebral conjunctiva, and 2 in the fornix. The mean Breslow thickness of conjunctival melanomas was 2.3 mm (range, 0.3-17.0 mm).
SNaPshot TERT Promoter Mutation Analysis
One of 102 uveal melanomas (1.0%) showed a 250C>T TERT promoter mutation. This tumor had a disomy of chromosomes 1p and 3, and a gain of chromosomes 6 and 8. In addition, this sample harbored a heterozygous GNA11 mutation in exon 5 (p.Q209L) and had normal BAP1 staining, consistent with a primary low-risk uveal melanoma signature. Blood of this patient was available for TERT analyses revealing a wild-type status. A total of 16 TERT promoter mutations, three 228C>T, two 242CC>TT, and eleven 250C>T, were found in the 39 conjunctival melanomas (41.0%); and 2 of 25 (8.0%) PAM with atypia showed a mutation, one 228C>T ( Fig. 1 ) and one 250C>T (Fig. 2 , Table 3 ). In one case a conjunctival nevus and a conjunctival melanoma were analyzed from the same patient as unrelated lesions. In seven cases, concurrent PAM and conjunctival melanoma were analyzed from the same patient.
In none of these cases did the lesion contain a TERT promoter mutation. In the two cases of PAM with atypia that carried TERT promoter mutations, one recurred once as a PAM with atypia and was then radically excised; the other case also had one recurrence as PAM with atypia, which was irradically excised. Subsequently, both these patients received successful additional treatment with cryotherapy and topical mitomycin C with no recurrences. No TERT promoter mutations were identified in 13 PAM without atypia and 56 conjunctival nevi patients (16 stromal and 40 compound nevi).
Correlations of TERT Promoter Mutation Status With Clinicopathologic Patient Characteristics
The patients with a wild-type tumor (P ¼ 0.272, Fig. 3A ). In total, 8 of 39 patients with conjunctival melanoma developed metastatic disease; four of these tumors harbored a TERT mutation (P ¼ 0.527, Fig. 3B ). Three out of 16 mutated conjunctival melanoma cases died from metastatic disease compared to none of the wild-type cases.
DISCUSSION
Melanomas are the most common lethal primary ocular cancers. In the ophthalmic practice, melanomas mainly occur in two types, uveal melanoma and conjunctival melanoma, which differ in both genetic and molecular background. We detected TERT promoter mutations in a high percentage (41%) of conjunctival melanomas as compared to only 1% of uveal melanomas. These results are in accordance with one other cohort in which TERT promoter mutations were detected in approximately one-third of conjunctival melanomas. 7 We present the second case of a TERT promoter mutation in an otherwise cytogenetically and molecularly unremarkable case of uveal melanoma. Both the TERT promoter mutated uveal melanoma described here and the TERT promoter mutation-positive uveal melanoma described by Dono et al. 9 have a cytogenetic low risk signature. Until now, TERT promoter mutations have been detected in only 1 of a total of 97 uveal melanoma-derived samples from two different cohorts. 7, 9 Uveal melanomas, in contrast to conjunctival melanomas, lack BRAF or NRAS mutations but frequently have GNAQ, GNA11, BAP1, or SF3B1 mutations. 9, 11 These findings confirm that since genetic alterations are different, 14 the molecular pathogenesis of uveal melanoma is distinct from that of conjunctival or cutaneous melanoma. In contrast to earlier reports, the mere presence of TERT promoter mutations cannot be used to distinguish primary uveal melanoma from (metastatic) cutaneous or conjunctival lesions. 7 The core promoter region of the TERT gene encodes the rate-limiting catalytic reverse transcriptase subunit of the telomerase ribonucleoprotein complex. The g.1295228C>T, g.1295250C>T, or less common g.1295242CC>TT mutations upstream of the transcription start site create de novo CCGGAA/T general binding motifs for E-twenty six/ternary complex factor (Ets/TCF) transcription factors, which differs from preexisting GGAA/T Ets binding sites within the TERT promoter. The Ets transcription factors are downstream targets of RAS-RAF-MAPK pathways, and TERT promoter mutations are suggested to have synergistic effects with activating BRAF or NRAS mutations to promoter tumor cell proliferation. BRAF and NRAS mutations have been proposed to be driver mutations in the development of cutaneous melanocytic neoplasms since they are present in both benign and malignant neoplastic lesions. 15, 16 We are the first to show the presence of TERT promoter mutations in a premalignant melanocytic lesion, PAM with atypia, and its absence in PAM without atypia and conjunctival nevi. The mutation frequency of 33% reported in primary cutaneous melanomas 6, 17 is similar to the mutation rate in primary conjunctival melanomas. Conjunctival melanomas, like cutaneous melanomas, frequently harbor BRAF or NRAS mutations. 7 The high frequency of TERT promoter mutations and the higher than expected rate of concomitant mutations in the TERT promoter and BRAF in cutaneous melanoma 6 might suggest that TERT promoter mutations are driver mutations in the pathogenesis of melanoma. However, in contrast to BRAF mutations, TERT promoter mutations were not identified in benign cutaneous nevi (n ¼ 34), 6, 17 nor in conjunctival nevi 7 or PAM without atypia. The possible role of TERT promoter mutations in molecular progression is demonstrated by the identification of these mutations in a low percentage of premalignant melanocytic lesions, PAM with atypia, and in a higher percentage in conjunctival melanoma. In the past, it has been observed that atypia does lead to a highly increased chance for malignant progression. Although our cohort contained only 14 cases of PAM without atypia, this would be in agreement with that observation. The acquisition of TERT promoter mutations can be hypothesized to facilitate stabilization of the transformed genome through reversal of telomeric loss. Many conjunctival melanocytic nevi carry BRAF mutations, 18 whereas TERT promoter mutations are detected only in primary melanoma and, as we have shown, in PAM with atypia. In cutaneous squamous cell carcinoma lesions a similar role for TERT promoter mutations can be observed, with mutations in 50% of squamous cell carcinomas and 9% of Bowen's disease (in situ lesions). In contrast, the role for TERT promoter mutations as a driver mutation is more convincing in urothelial cell neoplasms, where TERT promoter mutations are present in a high percentage (74%) in both low-grade and high-grade in situ urothelial cell carcinoma 13, 19 as well as in invasive urothelial cell carcinoma (53%). 13, 20 The increased telomerase expression associated with TERT promoter mutations 5 offers new therapeutic possibilities in TERT mutated conjunctival melanoma. General reverse transcriptase inhibitors such as AZT (azidothymidine), which acts on the reverse transcriptase activity of TERT, may warrant investigation for potential therapeutic potential in conjunctival melanoma with TERT promoter mutations. 21 Another way to inhibit telomerase function is to reduce levels of TERT transcripts. The telomerase nucleotide bases inhibitor, imetelstat (GRN163L), has shown effectiveness in melanoma cell lines 22 and entered phase I 23 and II clinical trials for other tumor types. More specific chemical inhibitors of telomere extension, MST-312, BIBR1532, brubromycin, PIPER {N,N0-bis [2-(1-piperidino) ethyl]-3,4,9,10tetracarboxylic diimide}, and TmPyP4 are in an experimental phase at this moment. 24 In conclusion, we present the first data on TERT promoter mutations in PAM with atypia and propose its possible role as a molecular tumor progression marker for conjunctival melanocytic lesions.
